Fig. 1 · Structure

Documents & Downloads

Loteprednol Etabonate

Cat. No. A10539 CAS 82034-46-6
Loteprednol Etabonate is an ophthalmic corticosteroid. It is used as an anti-inflammatory.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Loteprednol etabonate suppresses cytokine-stimulated, NF-κB-inducible reporter output in engineered HEK293-derived sensor cells. Suppression was partial and depended on the cytokine stimulus, supporting a functional anti-inflammatory signaling effect in this assay. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Glucocorticoid receptor

Cellular Effect

Cell Line Activity Value Description Reference
Caco-2 IC50 17.92 μM Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging 10.21203/rs.3.rs-23951/v1
Caco-2 CC50 49.03 μM Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay 10.21203/rs.3.rs-23951/v1

Loteprednol Etabonate Research Summary

This section summarizes 1 in vitro study of Loteprednol Etabonate from 1 published reference.

Loteprednol Etabonate In Vitro Studies

Reported fitted IC₅₀ values were 0.79 nM for TNFα-induced and 0.06 nM for CD40L-induced reporter activity. The fitted maximum suppression was approximately 30% and 40%, respectively. These IC₅₀ values describe half of each partial maximum, rather than 50% inhibition of the total stimulated signal. [1]

Partial suppression of cytokine-induced reporter activity

Cell-based study · HEK-Blue CD40L sensor cells derived from HEK293, with transfected human CD40 and an NF-κB-inducible SEAP reporter; TNF receptors expressed endogenously. [1]

Loteprednol etabonate partially suppressed TNFα- and CD40L-stimulated reporter output in a concentration-dependent manner. The two stimulus branches form one comparative reporter study. Different fitted potencies are model- and stimulus-dependent; the experiments do not establish direct binding to NF-κB or a clinical dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TNFα (3 ng/mL)-induced NF-κB-inducible SEAP output, expressed as suppression relative to stimulation aloneReported fitted IC50 0.79 nM[1]
CD40L (25 ng/mL)-induced NF-κB-inducible SEAP output, expressed as suppression relative to stimulation aloneReported fitted IC50 0.06 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Methods lists 0, 0.01, 0.1, 1.0, 10, 100 and 1000 nM corticosteroid; TNFα 3 ng/mL or CD40L 25 ng/mL.
Exposure duration
20 h with TNFα; 30 h with CD40L. TNFα results pool experiments with and without 6 h drug pre-incubation after no significant difference was found.
Method
Cytokine stimulation in the presence of each separately tested corticosteroid; secreted alkaline phosphatase readout with QUANTI-Blue.
Co-treatment
LE plus the indicated cytokine stimulus; other corticosteroids were parallel comparators, not combination treatments.
Reported limits
Drug stock solvent and matching solvent-control details are not specified in the acquired manuscript. Figure curves include lower-concentration points than the Methods list; no additional concentrations are reconstructed.
Methods and source locations

Compound reported in the paper: Loteprednol etabonate; Compound label in the paper: LE

Results for the published test material in engineered sensor cells; no Adooq lot validation or inference of ophthalmic formulation performance.

Sections 2.1–2.3, 3.1–3.2; Table 1, LE column; Figures 2 and 4 with captions; Discussion

TNFα (3 ng/mL)-induced NF-κB-inducible SEAP output, expressed as suppression relative to stimulation alone: Concentration-response fit with shared Emax = 30% and Hill slope = 0.5. IC50 denotes half the fitted partial maximum, not 50% inhibition of total stimulated signal. Five independent experiments, triplicate or quadruplicate wells per condition. — Table 1, LE column; Section 3.1; Figure 2 and caption; Sections 2.2–2.3

CD40L (25 ng/mL)-induced NF-κB-inducible SEAP output, expressed as suppression relative to stimulation alone: Concentration-response fit with shared Emax = 40% and Hill slope = 0.5. IC50 denotes half the fitted partial maximum, not 50% inhibition of total stimulated signal. Five independent experiments, triplicate or quadruplicate wells per condition. — Table 1, LE column; Section 3.2; Figure 4 and caption; Sections 2.2–2.3

Specifications

Manufacturer Adooq Bioscience
CAS Number 82034-46-6
Formula C24H31ClO7
Molecular Weight 466.96
SMILES
CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 82 mg/mL (175.6 mM)
Water Insoluble
Ethanol 4 mg/mL (8.56 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Loteprednol Etabonate Research References

  1. [1] Sirlene R. Cechin, Peter Buchwald. Effects of representative glucocorticoids on TNFα- and CD40L-induced NF-κB activation in sensor cells Steroids (2014). PMID: 24747770 DOI: 10.1016/j.steroids.2014.04.003 Source material

Added to your cart

View Cart Checkout
Loading...